INHIBITEURS D'OLIGONUCLÉOTIDES ANTISENS (ASO) DIRIGÉS CONTRE LE TRANSPORTEUR DE MONOCARBOXYLATE 4 (MCT4) UTILISÉS COMME AGENTS THÉRAPEUTIQUES DANS LE TRAITEMENT DU CANCER
Provided herein are compositions, method and uses for modulating MCT4 activity or for the treatment of cancer. The compositions comprise antisense oligonucleotides (ASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of MCT4. The cancer may be selected from one or more of: prostate cancer; renal cell carcinoma; breast cancer; cervical cancer; liver cancer; bladder cancer; and small cell lung cancer pr. The prostate cancer may be castration-resistant prostate cancer (CRPC).